OS Animal Health to Showcase Canine Cancer Immunotherapy at Moody Capital Conference

OS Animal Health, a wholly owned subsidiary of OS Therapies Inc. (NYSE American: OSTX), is set to be featured in coverage of the upcoming Moody Capital Solutions 2026 Disruptive Growth and Life Sciences Conference. The company, dedicated to improving outcomes for pets with cancer, is focused on developing and commercializing OST-HER2 for canine osteosarcoma, a devastating bone cancer that primarily affects large and giant breed dogs.

The conference, organized by Moody Capital Solutions Inc., an independent investment bank with over 40 years of experience in capital raising, M&A, and advisory services, will spotlight companies at the forefront of disruptive growth in life sciences. OS Animal Health's participation underscores the growing importance of veterinary oncology as a sector with significant economic potential.

OST-HER2 is being positioned as the “go-to” option for all HER2 positive cancers in dogs, and eventually for all companion animals. This innovative immunotherapy could revolutionize the treatment of canine cancers, which affect hundreds of thousands of pets each year. According to the National Canine Cancer Foundation, approximately 1 in 4 dogs will develop cancer at some point in their lives, making it the leading cause of death in dogs over the age of two.

The company is working to re-establish USDA conditional approval for OST-HER2, a critical step towards bringing this therapy to market. If successful, OST-HER2 would be the first USDA-approved immunotherapy for canine osteosarcoma, offering a new treatment option that could extend and improve the lives of affected pets.

The economic implications are substantial. The global veterinary oncology market was valued at over $1 billion in 2023 and is projected to grow at a compound annual growth rate of over 8% in the coming years. With Texas being a major hub for veterinary medicine and pet ownership, the introduction of an effective canine cancer treatment could have a significant impact on the state's veterinary industry and economy.

OS Therapies has been actively engaging with the investor community, with Investor Relations contact Harrison Seidner, PhD of WaterSeid Partners available for inquiries. The company also maintains a presence on social media platforms, including X, Instagram, Facebook, and LinkedIn, to keep stakeholders informed about its progress.

The conference is scheduled to take place in the near future, and registration is available through the Moody Capital website. IBN, a multifaceted financial news and publishing company, will provide comprehensive coverage of the event, including summaries of participating companies and syndication across its network of financial websites.

For more information about OS Animal Health and its parent company, visit the company’s website at https://ostherapies.com/. To register for the conference, visit https://moodycapital.com/conference/. IBN’s coverage of the conference can be accessed at https://ibn.fm/MoodyCapital2026Conference.

The focus of OS Animal Health on canine osteosarcoma is notable because osteosarcoma is an aggressive cancer with a poor prognosis, and current treatments often involve amputation and chemotherapy, which have significant side effects. OST-HER2 represents a targeted therapy approach that could offer a more effective and less invasive treatment option.

As the company progresses towards regulatory approval, its success could pave the way for other veterinary immunotherapies, opening new avenues for animal health companies and benefiting pets and their owners worldwide. The presentation at the Moody Capital conference provides an opportunity for investors and industry stakeholders to learn more about these developments and the potential market impact.